The DOI matches its Crossref record.
Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity
Abstract
We analyzed mutations of 7 vitamin K—dependent protein and cytochrome P450 2C9 genes in 45 patients and investigated whether any contribute to the large interpatient variability in the warfarin dose-effect relationship. Total clearance and daily dose, INR and INR/Cp, were used as pharmacokinetic and pharmacodynamic indexes, respectively. Patients were grouped by genotype based on a single polymorphism and combinations of polymorphisms. Among the 30 sequence variants identified, CYP2C9*3, 165Thr → Met of the factor II gene, -402G → A, (37-bp repeat)n, and -746T → C of the factor VII gene, and (CAA repeat)n of the γ-glutamyl carboxylase gene were selected as candidate polymorphisms. As the analysis of single polymorphisms implied, the highest INR/Cp mean values and the lowest warfarin maintenance doses were observed in patients homozygous for the 165Met, -402G, (37-bp repeat)6 and -746T alleles. Multiple regression analysis revealed that warfarin sensitivity was independently associated with -402G → A, (CAA repeat)n, CYP2C9*3, and 165Thr → Met, which accounted for 50% of variance. These results suggest that part of the considerable interpatient variation is attributable to genetic variation, and the combined genotyping of CYP2C9 and certain vitamin K—dependent protein genes is useful for predicting anticoagulant responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sconce, E. A., Khan, T. I., Wynne, H. A., Avery, P., Monkhouse, L., King, B. P., Wood, P., Kesteven, P., Daly, A. K., & Kamali, F. (2005) · Blood · doi:10.1182/blood-2005-03-1108 · Cited by 947
Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin
Gage, B., Eby, C., Johnson, J., Deych, E., Rieder, M., Ridker, P., Milligan, P., Grice, G., Lenzini, P., Rettie, A., et al. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.10 · Cited by 847
The largest prospective warfarin-treated cohort supports genetic forecasting
Wadelius, M., Chen, L. Y., Lindh, J. D., Eriksson, N., Ghori, M. J. R., Bumpstead, S., Holm, L., McGinnis, R., Rane, A., & Deloukas, P. (2009) · Blood · doi:10.1182/blood-2008-04-149070 · Cited by 550
Clinical consequences of cytochrome P450 2C9 polymorphisms
KIRCHHEINER, J., & BROCKMOLLER, J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.08.009 · Cited by 474
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
Wadelius, M., Chen, L. Y., Downes, K., Ghori, J., Hunt, S., Eriksson, N., Wallerman, O., Melhus, H., Wadelius, C., Bentley, D., et al. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500313 · Cited by 468
Metadata
- Authors
- Shikata, E., Ieiri, I., Ishiguro, S., Aono, H., Inoue, K., Koide, T., Ohgi, S., & Otsubo, K.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2004-04-01
- Volume
- 103
- Issue
- 7
- Pages
- 2630-2635
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2396892581
- Cited by
- 159
- References
- 0
- FWCI
- 11.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity. https://app.cochat.ai/papers/10.1182/blood-2003-09-3043
- The paper
- Shikata, E., Ieiri, I., Ishiguro, S., Aono, H., Inoue, K., Koide, T., Ohgi, S., & Otsubo, K. (2004). Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood. https://doi.org/10.1182/blood-2003-09-3043
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.